Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing

Prostate

Volumn 75, Issue 5, 2015, Pages 500-516

  Song, Chunjiao ^a   Chen, Huan ^b   Wang, Tingzhang ^b   Zhang, Weiguang ^a   Ru, Guomei ^a   Lang, Juan ^a  

^a SHAOXING PEOPLE S HOSPITAL   (China)

^b Zhejiang Institute of Microbiology   (China)

Author keywords

MicroRNA; Next generation sequencing; Pathway enrichment analysis; Prostate cancer

Indexed keywords

MICRORNA; MICRORNA 125B; MICRORNA 125B 5P; MICRORNA 126; MICRORNA 126 5P; MICRORNA 151A 5P; MICRORNA 221; MICRORNA 221 3P; MICRORNA 222; MICRORNA 222 3P; MICRORNA 486 5P; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; MALE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA SEQUENCE; SIGNAL TRANSDUCTION; VERY ELDERLY; BIOLOGY; CHINA; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; CHINA; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84923482388     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22936     Document Type: Article

References (72)

1. Giraldez AJ, Mishima Y, Rihel J., Grocock RJ, Van Dongen S, Inoue K, Enright A.J., Schier AF. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science 2006; 312(5770):75-79.
2. Höock J, Meister G. The Argonaute protein family. Genome Biol 2008; 9(2):210.
3. Meister G. MiRNAs get an early start on translational silencing. Cell 2007; 131(1):25-28.
4. Wiklund ED, Kjems J, Clark SJ. Epigenetic architecture and miRNA: Reciprocal regulators. Epigenomics 2010; 2(6):823-840.
5. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11(9):597-610.
6. Siomi H, Siomi MC. Posttranscriptional regulation of micro-RNA biogenesis in animals. Mol Cell 2010; 38(3):323-332.
7. Lee EJ, Baek M, Gusev Y., Brackett DJ, Nuovo GJ, Schmittgen TD. Systematic evaluation of microRNA processing patterns in tissues cell lines tumors. RNA 2008; 14(1):35-42.
8. Szczyrba J, Löoprich E, Wach S., Jung V, Unteregger G, Barth S., Grobholz R, Wieland W, Stoöhr R, Hartmann A, Wullich B, Gröasser F. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 2010; 8(4):529-538.
9. Carlsson S, Vickers AJ, Roobol M, Eastham J., Scardino P, Lilja H, Hugosson J. Prostate cancer screening: Facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol 2012; 30(21):2581-2584.
10. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11-30.
11. Martens-Uzunova ES, Jalava SE, Dits N.F., van Leenders GJ, Møller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G. Diagnostic and prognostic signatures from the small noncoding RNA transcriptome in prostate cancer. Oncogene 2012; 31(8):978-991.
12. Porkka KP, Pfeiffer MJ, Waltering K.K., Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67(13):6130-6135.
13. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27(12):1788-1793.
14. Ambs S, Prueitt RL, Yi M, Hudson R.S., Howe TM, Petrocca F, Wallace TA, Liu C.G., Volinia S., Calin GA, Yfantis HG, Stephens RM, Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68(15):6162-6170.
15. Creighton CJ, Reid JG, Gunaratne PH. Expression profiling of microRNAs by deep sequencing. Brief Bioinform 2009; 10(5): 490-497.
16. Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of ProstaticCarcinoma. Am J Surg Pathol 2005; 29(9): 1228-1242.
17. Xi Y, Nakajima G, Gavin E., Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen formalin-fixed paraffin-embedded samples. RNA 2007; 13(10):1668-1674.
18. Langmead B, Trapnell C, Pop M., Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10(3):R25.
19. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3(6):1101-1108.
20. Wang X. MiRDB: A microRNA target prediction functional annotation database with a wiki interface. RNA 2008; 14(6):1012-1017.
21. Paraskevopoulou MD, Georgakilas G, Kostoulas N., Vlachos IS, Vergoulis T, Reczko M, Filippidis C., Dalamagas T, Hatzigeorgiou AG. DIANA-microT web server v5.0: Service integration into miRNA functional analysis workflows. Nucleic Acids Res 2013; 41:W169-W173.
22. Li C, Li X, Miao Y., Wang Q, Jiang W, Xu C., Li J, Han J, Zhang F, Gong B, Xu L. SubpathwayMiner: A software package for flexible identification of pathways. Nucleic Acids Res 2009; 37(19):e131.
23. Papadopoulos GL, Alexiou P, Maragkakis M., Reczko M, Hatzigeorgiou AG. DIANA-mirPath: Integrating human and mouse microRNAs in pathways. Bioinformatics 2009; 25(15): 1991-1993.
24. Cinti C, Vindigni C, Zamparelli A., La Sala D, Epistolato MC, Marrelli D, Cevenini G., Tosi P. Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch 2008; 453(5):449-455.
25. Pappas G, Zumstein LA, Munshi A, Hobbs M., Meyn RE. Adenoviral-mediated PTEN expression radiosensitizes nonsmall cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther 2007; 14(6):543-549.
26. Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 2013; 6:6.
27. Shi XB, Xue L, Yang J., Ma AH, Zhao J, Xu M, Tepper C.G., Evans CP, Kung HJ, deVere White RW An androgen-regulated miRNA suppresses Bak1 expression and induces androgenindependent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104(50):19983-19988.
28. Giray BG, Emekdas G, Tezcan S., Ulger M, Serin MS, Sezgin O, Altintas E., Tiftik EN. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep 2014; 41(7):4513-4519.
29. Bi Q, Tang S, Xia L., Du R, Fan R, Gao L., Jin J, Liang S, Chen Z, Xu G, Nie Y, Wu K, Liu J, Shi Y, Ding J, Fan D. Ectopic expression of MiR-125a inhibits the proliferation and metastasis ofhepatocellular carcinoma by targeting MMP11 and VEGF. PLoS ONE 2012; 7(6):e40169.
30. Xu N, Zhang L, Meisgen F., Harada M, Heilborn J, Homey B., Grander D, Stahle M, Sonkoly E, Pivarcsi A. MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibitscutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J Biol Chem 2012; 287(35):29899-29908.
31. Shaham L, Binder V, Gefen N., Borkhardt A, Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012; 26(9): 2011-2018.
32. Manfè V, Biskup E, Willumsgaard A, Skov AG, Palmieri D, Gasparini P, Lagana A, Woetmann A, Ødum N, Croce CM, Gniadecki R. CMyc/miR-125b-5p signalling determines sensitivity to bortezomib inpreclinical model of cutaneous T-cell lymphomas. PLoS ONE 2013; 8(3):e59390.
33. Bousquet M, Nguyen D, Chen C., Shields L, Lodish HF. Micro-RNA-125b transforms myeloid cell lines by repressing multiple mRNA. Haematologica 2012; 97(11):1713-1721.
34. Ge Y, Sun Y, Chen J. IGF-II is regulated by microRNA-125b in skeletal myogenesis. J Cell Biol 2011; 192(1):69-81.
35. Le MT, Teh C, Shyh-Chang N, Xie H., Zhou B, Korzh V, Lodish H.F., Lim B. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23(7):862-876.
36. Wu Z, Yin H, Liu T., Yan W, Li Z, Chen J., Chen H, Wang T, Jiang Z, Zhou W, Xiao J. MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13. Biochem Biophys Res Commun 2014; 443(3):944-949.
37. Zhou W, Yin H, Wang T., Liu T, Li Z, Yan W., Song D, Chen H, Chen J, Xu W, Yang X, Wu Z, Xiao J. MiR-126-5p regulates osteolysis formation and stromal cell proliferation in giant cell tumor through inhibition of PTHrP. Bone 2014; 66:267-276.
38. McNally ME, Collins A, Wojcik S.E., Liu J., Henry JC, Jiang J, Schmittgen T, Bloomston M. Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma. HPB (Oxford) 2013; 15(4):260-264.
39. ∗: New players in cancer. Scientific World Journal 2010; 10:2090-2100.
40. Bisio A, De Sanctis V, Del Vescovo V, Denti MA, Jegga AG, Inga A, Ciribilli Y. Identification of new p53 target microRNAs by bioinformatics and functional analysis. BMC Cancer 2013; 13:552.
41. Krell J, Frampton AE, Jacob J, Pellegrino L., Roca-Alonso L, Zeloof D, Alifrangis C., Lewis JS, Jiao LR, Stebbing J, Castellano L. The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis. Mol Diagn Ther 2012; 16(3): 167-172.
42. Chiyomaru T, Yamamura S, Zaman M.S., Majid S., Deng G, Shahryari V, Saini S., Hirata H, Ueno K, Chang I, Tanaka Y, Tabatabai ZL, Enokida H, Nakagawa M, Dahiya R. Genistein suppresses prostate cancer growth through inhibition of oncogenic microRNA-151. PLoS ONE 2012; 7(8):e43812.
43. Hwang MS, Yu N, Stinson S.Y., Yue P., Newman RJ, Allan BB, Dornan D. MiR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS ONE 2013; 8(6):e66502.
44. Ye X, Bai W, Zhu H., Zhang X, Chen Y, Wang L., Yang A, Zhao J, Jia L. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep 2014; 47(5):268-273.
45. Garofalo M, Di Leva G, Romano G, Nuovo G., Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM. MiR-221 and 222 regulate TRAIL resistance and enhance tumorigenicitythrough PTEN and TIMP3 downregulation. Cancer Cell 2009; 16(6):498-509.
46. Tao K, Yang J, Guo Z., Hu Y, Sheng H, Gao H., Yu H. Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res 2014; 6(4):391-401.
47. Sun K, Wang W, Zeng J.J., Wu CT, Lei ST, Li GX. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin 2011; 32(3):375-384.
48. Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett 2014; 588(1):99-104.
49. Xue Q, Sun K, Deng H.J., Lei ST, Dong JQ, Li GX. Anti-miRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN. World J Gastroenterol 2013; 19(48):9307-9317.
50. Felicetti F, Errico MC, Bottero L, Segnalini P., Stoppacciaro A, Biffoni M, Felli N., Mattia G, Petrini M, Colombo MP, Peschle C, Carè A. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68(8): 2745-2754.
51. Sarkar S, Dubaybo H, Ali S., Goncalves P, Kollepara SL, Sethi S, Philip P.A., Li Y. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN,N, p27 (kip1), p57(kip2), and PUMA. Am J Cancer Res 2013; 3(5):465-477.
52. Karakatsanis A, Papaconstantinou I, Gazouli M., Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013; 52(4):297-303.
53. Zhang C, Zhang J, Hao J., Shi Z, Wang Y, Han L., Yu S, You Y, Jiang T, Wang J, Liu M, Pu P, Kang C. High level of miR-221/222 confers increased cell invasion and poorprognosis in glioma. J Transl Med 2012; 10:119.
54. Liu B, Che Q, Qiu H., Bao W, Chen X, Lu W., Li B, Wan X. Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERa. PLoS ONE 2014; 9(1):e87563.
55. Sun T, Wang Q, Balk S., Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent-prostate cancer cell lines. Cancer Res 2009; 69(8):3356-3363.
56. Xu G, Wu J, Zhou L., Chen B, Sun Z, Zhao F., Tao Z. Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing. PLoS ONE 2010; 5(11):e15519.
57. Walter BA, Valera VA, Pinto P.A., Merino MJ. Comprehensive microRNA profiling of prostate cancer. J Cancer 2013; 4(5):350-357.
58. Kneitz B, Krebs M, Kalogirou C., Schubert M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Stroöbel P, Gessler M, Riedmiller H, Spahn M. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res 2014; 74(9):2591-2603.
59. Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013; 4(2):242-255.
60. Stinson S, Lackner MR, Adai A.T., Yu N., Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S., Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal 2011; 4(177):ra41.
61. Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol 2013; 75:225-240.
62. Galardi S, Mercatelli N, Giorda E., Massalini S, Frajese GV, Ciafrè SA, Farace MG. MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282(32):23716-23724.
63. Wang J, Tian X, Han R., Zhang X, Wang X, Shen H., Xue L, Liu Y, Yan X, Shen J, Mannoor K, Deepak J, Donahue JM, Stass SA, Xing L, Jiang F. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene 2014; 33(9):1181-1189.
64. Shen J, Liu Z, Todd N.W., Zhang H., Liao J, Yu L, Guarnera M.A., Li R., Cai L, Zhan M, Jiang F. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma micro-RNA biomarkers. BMC Cancer 2011; 11:374.
65. Jiang F1, Yin Z, Caraway NP, Li R, Katz RL. Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia 2004; 6(5):623-635.
66. Zhang G, Liu Z, Cui G., Wang X, Yang Z. MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol 2014; (Epub ahead of print).
67. Midorikawa Y, Yamamoto S, Tsuji S., Kamimura N, Ishikawa S, Igarashi H., Makuuchi M, Kokudo N, Sugimura H, Aburatani H. Allelic imbalances and homozygous deletion on 8p23.2 for stepwiseprogression of hepatocarcinogenesis. Hepatology 2009; 49(2):513-522.
68. Ragusa M, Majorana A, Statello L., Maugeri M, Salito L, Barbagallo D., Guglielmino MR, Duro LR, Angelica R, Caltabiano R, Biondi A, Di Vita M, Privitera G, Scalia M, Cappellani A, Vasquez E, Lanzafame S, Basile F, Di Pietro C, Purrello M. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 2010; 9(12):3396-3409.
69. Bansal A, Lee IH, Hong X, Anand V., Mathur SC, Gaddam S, Rastogi A, Wani S.B., Gupta N., Visvanathan M, Sharma P, Christenson LK. Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: A pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol 2011; 106(6):1055-1063.
70. Mees ST, Mardin WA, Sielker S, Willscher E., Senninger N, Schleicher C, Colombo-Benkmann M, Haier J. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009; 16(8):2339-2350.
71. Small EM, O'Rourke JR, Moresi V, Sutherland L.B., McAnally J., Gerard RD, Richardson JA, Olson EN. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A 2010; 107(9):4218-4223.
72. Oh HK, Tan AL, Das K, Ooi C.H., Deng NT, Tan IB, Beillard E, Lee J., Ramnarayanan K, Rha SY, Palanisamy N, Voorhoeve PM, Tan P. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res 2011; 17(9):2657-2667.